Affimed Announces Publication of AFM24 Clinical Abstracts for the Annual Meeting of the American Society of Clinical Oncology May 25, 2023
Affimed Reports First Quarter 2023 Financial Results and Highlights Operational Progress May 23, 2023
Affimed Announces IND Clearance for a Phase 2 Clinical Trial Investigating AFM13 and AB-101 Combination Therapy May 23, 2023
Affimed to Report First Quarter 2023 Financial Results & Corporate Update on May 23, 2023 May 16, 2023
Affimed Announces Abstracts at the Annual Meeting of the European Hematology Association May 11, 2023
Affimed Announces AFM24 Clinical Abstracts Accepted for the Annual Meeting of the American Society of Clinical Oncology (ASCO) April 26, 2023
Affimed Shares Preclinical Data on AFM13’s Mechanism of Action Demonstrating Its Potential to Induce Serial Killing at the American Association for Cancer Research Annual Meeting April 17, 2023
Affimed Presents Final Data Demonstrating Safety and Efficacy of AFM13 Phase 2 REDIRECT Study in Patients with Heavily Pretreated Relapsed or Refractory Peripheral T Cell Lymphoma at the American Association for Cancer Research Annual Meeting 2023 April 16, 2023
